<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Covid Vaccine Info</title>
    <link rel="stylesheet" href="covidvaccine.css">
    <link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro&display=swap" rel="stylesheet">
</head>
<body>
  
    <header id="one">
        <nav class="navbar">
            <div class="logo">
                Cv <span>Info</span>
            </div>
            <ul class="links">
                <li ><a  href="#one">Home</a></li>
                <li><a href="#two">Vaccines Available</a></li>
                <li><a href="#three">FAQ's</a></li>
                <li><a href="#three">Side Effects</a></li>
                <li><a href="#four">Booster Dose</a></li>
            </ul>
            <a href="#" class="button">
                <span class="line"></span>
                <span class="line"></span>
                <span class="line"></span>
            </a>
        </nav>
        <section class="first">
            <h1 data-aos="fade-down" data-aos-easing="linear" data-aos-duration="1500">Get All Your Doubts <br><span class="heading">Cleared!</span></h1>
        </section>
        
    </header>
     
    <section class="diffvaccines" id="two">
        <h1 class="firstheading">COVID-19 Vaccines Under Trials In India</h1>
        <div class="container">
            <div class="vaccine">
                <div data-aos="fade-right" data-aos-duration="1000">
                    <h3>Covaxin</h3>
                    <p>COVAXINTM, India's indigenous COVID-19 vaccine Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). This indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility.
    
                        The vaccine received approval from Drug Controller General of India (DCGI) for Phase I & II Human Clinical Trials and an Adaptive, Seamless Phase I, Followed by Phase II Randomized, Double blind, Multicentre Study to Evaluate the Safety, Reactogenicity, Tolerability and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152). <br><span>Phase I Human Clinical Trial COMPLETED| Phase II Human Clinical Trial COMPLETED| Phase III Human Clinical Trial ONGOING. </span></p>
                </div>
                
                 <img src="https://www.bharatbiotech.com/images/covaxin/bharat-biotech-covaxin-packshot.jpg" alt="" data-aos="zoom-in" data-aos-duration="1000">   
            </div>
            <div class="vaccine">
                <img src="https://cdn.dnaindia.com/sites/default/files/styles/full/public/2021/06/07/978153-covishield.jpg" alt="" data-aos="zoom-in" data-aos-duration="1000">
                <div data-aos="fade-left" data-aos-duration="1000">
                    <h3>Covishield</h3>
                    <p>The Serum Institute of India (SII) and Indian Council of Medical Research are jointly conducting a Phase II/III, Observer-Blind, Randomized, Controlled Study to Determine the Safety and Immunogenicity of Covishield (COVID-19 Vaccine) <br> <span>Participants enrollment and vaccination of Phase II/III Human Clinical Trial COMPLETED.</span></p>
                </div>

            </div>
            <div class="vaccine">
                <div data-aos="fade-right" data-aos-duration="1000">
                    <h3>ZyCoV-D</h3>
                    <p>Zydus Cadila, focused on discovering and developing NCEs, Novel Biologicals, Biosimilars and Vaccines, announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D. Safety in Phase I clinical trial of ZyCoV-D in healthy subjects established as endorsed by the independent Data Safety Monitoring Board (DSMB). Zydus commenced Phase II trial. <br><span>Phase I Human Clinical Trial COMPLETED| Phase II Human Clinical Trial COMPLETED| Phase III Human Clinical Trial ONGOING</span></p>
                </div>
                <img src="https://fl.thgim.com/the-nation/r7ygru/article32747423.ece/alternates/FREE_435/fl23ZydusCadilaZyCoV-D" alt="" data-aos="zoom-in" data-aos-duration="1000">
            </div>
            <div class="vaccine">
                <img src="https://resize.indiatvnews.com/en/resize/newbucket/1200_-/2021/06/sputnik-1623583117.jpg" alt="" data-aos="zoom-in" data-aos-duration="1000">
                <div data-aos="fade-left" data-aos-duration="1000">
                    <h3>Sputinik</h3>
                    <p>Dr Reddys Laboratories Limited and Sputnik LLC are jointly conducting Multi-centre, phase II/III adaptive clinical trial to assess safety and immunogenicity of Gam-COVID-Vac combined vector. <br><span> DCGI approval for Phase II & Phase III Human Clinical Trials RECEIVED</span></p>
                </div>
            </div>
            <div class="vaccine">
                <div  data-aos="fade-right" data-aos-duration="1000">
                    <h3>BBV154 - Intranasal vaccine</h3>
                    <p>Bharat Biotech is conducting Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenoviral vector COVID-19 vaccine (BBV154) in Healthy Volunteers. BBV154 is an intranasal vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.  Immune responses at the site of infection (in the nasal mucosa) – essential for blocking both infection and transmission of COVID-19 <br><span>DCGI approval for Phase I Human Clinical Trials RECEIVED</span></p>
                </div>
                <img src="https://www.bharatbiotech.com/images/web-banner-3.jpg" alt="" data-aos="zoom-in" data-aos-duration="1000">
            </div>
            
        </div>
    </section>

    <section class="third" id="three">

    
    <div class="third3">
        <h1 data-aos="fade-down" data-aos-duration="1000" class="thirdheading" >FAQ's</h1>
        <div class="about">
            <div class="q" data-aos="fade-right" data-aos-duration="1000" data-aos-offset="50"*>
              

               
                <h3>Which Covid vaccines are licensed in India?</h3>
                <p>Two vaccines were granted emergency use authorization by the Central Drugs Standard Control Organization (CDSCO) in India, Covishield® (AstraZeneca's vaccine manufactured by Serum Institute of India) and Covaxin® (manufactured by Bharat Biotech Limited). Sputnik - V has been granted EUA in the month of April 2021.</p>
            </div>
            <div class="q" data-aos="fade-left" data-aos-duration="1000" data-aos-offset="100">
                
                <h3>Have the vaccines undergone the needed clinical trials before EUA?</h3>
                <p>Both the Indian COVID-19 vaccines have completed their Phase I & II trials. Covishield® has completed its Phase III trials in UK and the bridging trial in India.</p>
            </div>
            <div class="q" data-aos="fade-right" data-aos-duration="1000" data-aos-offset="150">
                
                <h3>What is Phase I, II and III of clinical trial for a vaccine?</h3>
                <p>Vaccine trial phases includes:-

                    Pre-clinical: Vaccine development in laboratory animals
                    Phase 1 Clinical trial (small number of participants): Assess vaccine safety, immune response and determine right dosage (short duration)
                    Phase 2 Clinical trial (few hundred participants): Assess safety and the ability of the vaccine to generate an immune response (short duration)
                    Phase 3 Clinical trial (thousands of participants): Determine vaccine effectiveness against the disease and safety in a larger group of people.</p>
            </div>
             <div class="q"  data-aos="fade-left" data-aos-duration="1000" data-aos-offset="175"> 
               
                <h3>What is the composition of both the vaccines?</h3>
                <p>Composition of Covishield includes inactivated adenovirus with segments of Coronavirus, Aluminium Hydroxide Gel, L-Histidine, L-Histidine Hydrochloride Monohydrate, Magnesium Chloride Hexahydrate, Polysorbate 80, Ethanol, Sucrose, Sodium Chloride, and Disodium Edetate Dihydrate (EDTA). Composition of Covaxin includes inactivated Coronavirus, Aluminum Hydroxide Gel, TLR 7/8 Agonist, 2-Phenoxyethanol and Phosphate Buffered Saline [NKA1]</p>
            </div>
             <div class="q" data-aos="fade-right" data-aos-duration="1000" data-aos-offset="200"> 
                
                <h3>What is the dose schedule of both the vaccines?</h3>
                <p>The time interval between two doses of the Covishield vaccine has been extended from four-eight weeks to 12-16 weeks. The second dose of Covaxin can be taken four to six weeks after the first.</p>
            </div>
            <div class="q" data-aos="fade-left" data-aos-duration="1000" data-aos-offset="230"> 
                
                <h3>Do I have a choice of vaccine I will receive?</h3>
                <p>The vaccine will be supplied to various parts of India as per availability and distribution plan, beneficiaries load and so at present the option of choice of vaccine is not available.</p>
            </div>
        </div>
    
    </div>
    <img src="https://www.mohfw.gov.in/covid_vaccination/vaccination/dist/images/vaccine-infographic-desktop.jpg" alt="" data-aos="zoom-in" data-aos-duration="1500">
</section>

<section class="fourth" id="four">
    <h1 class="fourthheading" data-aos="zoom-in-right" data-aos-duration="1000">Booster <span>Dose</span> </h1>
    <p data-aos="zoom-in-right" data-aos-duration="1000">In medical terms, a booster dose is an extra administration of a vaccine after an earlier (primer) dose. After initial immunization, a booster injection or booster dose is a re-exposure to the immunizing antigen. It is intended to increase immunity against that antigen back to protective levels, after memory against that antigen has declined through time.</p>
    <h2 data-aos="zoom-in-right" data-aos-duration="1000">Recent Articles</h2>
    <ul>
        <li data-aos="fade-up" data-aos-duration="1000"><a href="https://www.thequint.com/coronavirus/faq/coronavirus-vaccine-third-booster-dose" target="_blank">Do You Need Third Booster Dose of COVID-19 Vaccine?</a></li>
        <li data-aos="fade-up" data-aos-duration="1000" ><a href="https://www.bbc.com/news/uk-england-cambridgeshire-57467632" target="_blank">Covid-19: Vaccine booster study begins in Cambridge</a></li>
        <li data-aos="fade-up" data-aos-duration="1000"><a href="https://zeenews.india.com/india/research-work-is-going-on-booster-dose-of-covid-19-vaccines-says-aiims-doctor-2369181.html" target="_blank">Research work is going on booster dose of COVID-19 vaccines, says AIIMS doctor</a></li>
        <li data-aos="fade-up" data-aos-duration="1000" ><a href="https://www.cnbc.com/2021/04/15/pfizer-ceo-says-third-covid-vaccine-dose-likely-needed-within-12-months.html" target="_blank">Pfizer CEO says third Covid vaccine dose likely needed within 12 months</a></li>
        
    </ul>
</section>
<footer>
    <div class="footer">
         <a href="https://www.instagram.com/" target="_blank"><img src="https://cdn.icon-icons.com/icons2/2066/PNG/512/instagram_icon_125245.png" alt="" ></a> 
         <a href="https://www.facebook.com/" target="_blank" ><img src="https://img.icons8.com/ios/452/facebook-new.png" alt=""></a>
         <a href="https://www.youtube.com/" target="_blank" ><img src="https://www.searchpng.com/wp-content/uploads/2019/02/Youtube-Black-Icon-PNG-715x715.png" alt="" ></a>
         <a href="https://www.linkedin.com/" target="_blank"><img src="https://www.iconpacks.net/icons/1/free-linkedin-icon-94-thumb.png" alt=""></a>
    </div>
    <div class="footer2">
        Copyright &copy; www.CvInfo.com | All rights reserved. 
    </div>
</footer>
<script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script>
<script>
    AOS.init();
  </script>
  <script>
      let buttons=document.getElementsByClassName('button')[0]
      let ul=document.getElementsByClassName('links')[0]
      buttons.addEventListener('click',()=>{
          ul.classList.toggle('active');
      })
  </script>
</body>
</html>